Trials / Completed
CompletedNCT03512288
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 460 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 42 Days – 98 Days
- Healthy volunteers
- Accepted
Summary
A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants
Detailed description
NOTE: Detailed description has not been entered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Multivalent | Pneumococcal conjugate vaccine |
| BIOLOGICAL | 13vPnC | Pneumococcal conjugate vaccine |
Timeline
- Start date
- 2018-04-16
- Primary completion
- 2020-02-11
- Completion
- 2020-02-11
- First posted
- 2018-04-30
- Last updated
- 2021-03-02
- Results posted
- 2021-03-02
Locations
39 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03512288. Inclusion in this directory is not an endorsement.